In a 70-year-old man with diabetes mellitus, hypertension, benign prostatic hyperplasia status post transurethral resection of the prostate, arthritis, cataract, and a prior transient ischemic attack, with normal electrocardiogram and two‑dimensional echocardiogram, what medications and management strategies are appropriate to restore his sexual activity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Restoration of Sexual Activity in a 70-Year-Old Man with Multiple Comorbidities

This patient should be started on a PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) after confirming his cardiovascular risk is low-to-intermediate and checking his morning testosterone level. 1

Cardiovascular Risk Stratification First

Before prescribing any erectile dysfunction treatment, you must ensure sexual activity is safe for this patient. His history of TIA places him in the indeterminate-risk category 2. However, his normal ECG and 2D-echo are reassuring.

Key decision point: Can he complete 4 minutes of the standard Bruce treadmill protocol (5-6 METs) without symptoms, arrhythmias, or fall in systolic blood pressure? 2

  • If yes: He is reclassified as low-risk and can safely engage in sexual activity with PDE5 inhibitor treatment
  • If no or unable to perform (due to arthritis): Consider chemical stress test (dipyridamole or adenosine with nuclear imaging) 2
  • If stress test is abnormal: Defer sexual activity until cardiac condition is stabilized and refer to cardiology 2

Laboratory Evaluation Required

Before initiating treatment, obtain 1:

  • Morning total testosterone (if not checked in last 12 months)
  • Glucose-lipid profile (given his diabetes)
  • Consider bioavailable or free testosterone if total testosterone is borderline

First-Line Pharmacological Treatment

PDE5 inhibitors are the first-line treatment with excellent cardiovascular safety profile in this population 1, 2. The 2025 EAU guidelines confirm no new cardiovascular safety concerns from extensive postmarketing surveillance 1.

PDE5 Inhibitor Selection

Choose based on intercourse frequency and patient preference 1:

  • Sildenafil: Standard option, taken 30-60 minutes before activity
  • Vardenafil: Available as tablets or orally disintegrating tablets (ODTs) for convenience
  • Tadalafil: Longer half-life (up to 36 hours), can be taken daily at lower dose or on-demand; also approved for BPH symptoms
  • Avanafil: Fastest onset of action

Clinical pearl: Tadalafil may be particularly advantageous in this patient given his BPH history post-TURP, as it has dual indication for both ED and lower urinary tract symptoms 1.

Optimizing His Cardiovascular Medications

Review his current antihypertensive regimen 2:

  • If on beta-blockers: Consider switching to nebivolol (has direct vasodilating properties and less likely to cause ED) 2
  • Preferred antihypertensives: Angiotensin receptor blockers (ARBs) are less likely to cause ED than diuretics 2
  • Continue statins: May improve erectile function, though evidence is mixed 2

Testosterone Replacement Therapy

If morning testosterone is low (<230 ng/dL) or intermediate (230-350 ng/dL): 2

  • Consider testosterone replacement therapy (intramuscular, transdermal, or oral) 1
  • Can be used as initial treatment OR added to PDE5 inhibitor therapy if PDE5 inhibitor alone fails 2
  • TTh combined with PDE5 inhibitors may help hypogonadal nonresponders 1

If PDE5 Inhibitors Fail

Before declaring treatment failure, verify: 1

  1. Appropriate medication timing and dosing
  2. Adequate sexual stimulation
  3. Patient education about realistic expectations

Second-line options if truly nonresponsive: 1

  • Switch to different PDE5 inhibitor (though evidence for switching is limited)
  • Add testosterone therapy if hypogonadal
  • Low-intensity shockwave therapy (LI-SWT): Showed benefit in PDE5I nonresponders, particularly when combined with daily tadalafil 1
  • Intracavernous injection therapy: Vasoactive drug injection remains available at any stage 1
  • Vacuum erection devices (VEDs): 90% initial efficacy, may be beneficial for older patients with infrequent intercourse 1

Psychosocial Intervention

Do not neglect the psychological component: Sexual skills training and cognitive behavioral therapy complement medical treatment effectively and can be delivered individually or online 1. Include partner in discussions when appropriate.

Special Considerations for This Patient

Diabetes Impact

His diabetes increases risk of ED treatment failure. Diabetic patients, particularly those with prior urinary retention or catheterization, have higher rates of persistent voiding dysfunction post-TURP 3, 4. This may affect sexual confidence and function.

Post-TURP Status

While TURP addresses BPH, it doesn't directly improve erectile function. His diabetes increases his risk of suboptimal outcomes from prostate surgery 3, 4, which may compound ED issues.

Arthritis Limitation

If he cannot perform standard exercise stress testing due to arthritis, chemical stress testing is mandatory before clearing him for sexual activity 2.

Critical Contraindication

Absolute contraindication: PDE5 inhibitors are contraindicated with nitrate use. Ensure he is not taking nitroglycerin or other nitrates for angina 2.

Follow-Up Strategy

  • Reassess cardiovascular status and treatment response regularly 2
  • Monitor blood pressure control (target <130/80 mmHg in diabetes) 5
  • Recheck testosterone if replacement therapy initiated
  • Adjust PDE5 inhibitor dose or switch agents if initial response inadequate

References

5
Research

Evidence-based approach for managing hypertension in type 2 diabetes.

Integrated blood pressure control, 2010

Related Questions

How should I approach a 65-year-old male presenting with abdominal heaviness and loss of appetite for 3–4 months, who has normal oxygen saturation, normal heart rate, stage 1 hypertension, and ultrasound findings of grade 1 fatty liver, a left renal calculus with concretions, and grade 1 prostatomegaly?
In a 59-year-old male with diabetes mellitus and hypertension, currently taking metformin 1000 mg twice daily and empagliflozin (Jardiance) 25 mg daily, who has elevated LDL cholesterol, elevated triglycerides, vitamin D deficiency, and an HbA1c of 7.1%, what is the optimal management plan?
In a 65-year-old woman with hypertension, diabetes mellitus, mild exertional chest pain, mild ST‑segment changes on electrocardiogram, normal echocardiogram, and good functional capacity, what is the risk of major cardiac complications for non‑cardiac surgery?
In a 68-year-old man with a history of diabetes mellitus and hypertension who presents with two hours of retrosternal chest pain, nausea, and sweating, blood pressure 112/77 mmHg, heart rate 78 beats per minute, and electrocardiogram showing ST‑segment elevation in leads II, III, and aVF, what is the most appropriate next step in evaluating this patient?
What is the appropriate management for a 52-year-old female with type 2 diabetes mellitus and hypertension, currently taking lisinopril 10 mg daily and metformin 500 mg three times daily, with an HbA1c of 8.9% and otherwise normal laboratory results?
Which vitamins are recommended for a patient with sickle‑cell disease who is receiving antibiotics and ulcer treatment?
In a post‑menopausal woman taking finasteride and losartan, how should spironolactone be used for female‑pattern hair loss, including dosing and potassium monitoring?
Which vitamins should be prescribed for a patient with sickle cell anemia and a lower‑extremity wound?
How does neutrophil gelatinase-associated lipocalin (NGAL) compare to the combined biomarker tissue inhibitor of metalloproteinases‑2 (TIMP‑2) multiplied by insulin‑like growth factor‑binding protein‑7 (IGFBP‑7) for early risk stratification of acute kidney injury (AKI)?
A patient 10 days after sleeve gastrectomy presents with leg pain and warmth suggestive of deep vein thrombosis (DVT); what is the next step in management?
Should I add Celin 500 mg (calcium carbonate) and Neurobian Forte (B‑vitamin complex) to my Renoxia (minoxidil) cyclic therapy for hair?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.